Previous Article | Next Article 
Molecular and Cellular Biology, September 1999, p. 6323-6332, Vol. 19, No. 9
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Activating Signal Cointegrator 1, a Novel Transcription
Coactivator of Nuclear Receptors, and Its Cytosolic
Localization under Conditions of Serum Deprivation
Han-Jong
Kim,1
Ji-Young
Yi,2
Hee-Sook
Sung,1
David D.
Moore,3
Byung Hak
Jhun,2
Young Chul
Lee,1 and
Jae Woon
Lee1,4,*
Center for Ligand and
Transcription1 and Hormone Research
Center,4 Chonnam National University,
Kwangju 500-757, and College of Pharmacy, Pusan National
University, Pusan 609-735,2 Korea, and
Department of Cell Biology,3 Baylor
College of Medicine, Houston, Texas 770303
Received 20 October 1998/Returned for modification 14 December
1998/Accepted 14 June 1999
 |
ABSTRACT |
Activating signal cointegrator 1 (ASC-1) harbors an autonomous
transactivation domain that contains a putative zinc finger motif which
provides binding sites for basal transcription factors TBP and TFIIA,
transcription integrators steroid receptor coactivator 1 (SRC-1) and
CBP-p300, and nuclear receptors, as demonstrated by the glutathione
S-transferase pull-down assays and the yeast two-hybrid
tests. The ASC-1 binding sites involve the hinge domain but not the
C-terminal AF2 core domain of nuclear receptors. Nonetheless, ASC-1
appears to require the AF2-dependent factors to function (i.e.,
CBP-p300 and SRC-1), as suggested by the ability of ASC-1 to coactivate
nuclear receptors, either alone or in cooperation with SRC-1 and p300,
as well as its inability to coactivate a mutant receptor lacking the
AF2 core domain. By using indirect immunofluorescence, we further show
that ASC-1, a nuclear protein, is localized to the cytoplasm under
conditions of serum deprivation but is retained in the nucleus when it
is serum starved in the presence of ligand or coexpressed CBP or SRC-1.
These results suggest that ASC-1 is a novel coactivator molecule of
nuclear receptors which functions in conjunction with CBP-p300 and
SRC-1 and may play an important role in establishing distinct
coactivator complexes under different cellular conditions.
 |
INTRODUCTION |
The nuclear receptor superfamily is
a group of ligand-dependent transcriptional regulatory proteins that
function by binding to specific DNA sequences named hormone response
elements in the promoters of target genes (reviewed in reference
36). The superfamily includes receptors for a
variety of small hydrophobic ligands, such as steroids, T3, and
retinoids, as well as a large number of related proteins that do not
have known ligands, referred to as orphan nuclear receptors. Functional
analysis of nuclear receptors has shown that there are two major
activation domains. The N-terminal domain (AF1) contains a
ligand-independent activation function, whereas the extreme C-terminal
helix of the ligand binding domain (LBD) serves as an integral
component of the ligand-dependent transactivation function AF2, which
also includes several essential helixes in broad parts of the LBD. This
C-terminal AF2 core region, which is relatively highly conserved among
nuclear receptors, undergoes an allosteric change upon ligand binding,
and deletion or point mutations in this region often impair
transcriptional activation without changing ligand and DNA binding
affinities (36).
Transcriptional activation of nuclear receptors appears to involve at
least two separate processes: derepression and activation. Repression
is mediated in part by the interaction of unliganded receptors with
corepressors such as the nuclear receptor corepressor (N-CoR)
(8) and SMRT (20). However, ligand binding
triggers the dissociation of these corepressors and the concomitant
recruitment of coactivators. These putative receptor-interacting
coactivators include RIP-140 and RIP-160 (5, 6), ERAP-140
and ERAP-160 (17), TIF1 (28), TRIP1
(30), ARA70 (55), CBP and its functional homolog
p300 (16), steroid receptor coactivator 1 (SRC-1) (42, 54), xSRC-3 (25), AIB1 (1), TIF2
(50), RAC3 (34), ACTR (9), TRAM-1
(47), and p/CIP (48). In particular, the last eight proteins are highly related to each other and can enhance transcriptional activation by several nuclear receptors. These coactivators are postulated to function in transmitting the signal of
ligand-induced conformational change to the basal transcription machinery. As expected, many coactivators fail to interact with nuclear
receptors mutated for the C-terminal AF2 core region (6, 28,
50). Recently, chromatin remodeling by cofactors was also suggested to contribute, through histone acetylation-deacetylation, to
receptor-mediated transcriptional regulation (49, 52, 56). Accordingly, SRC-1 (46) and its homologue ACTR
(9), along with CBP-p300 (3, 41), were shown to
contain histone acetyltransferase activities and form a complex with
histone acetyltransferase protein P/CAF (53). In contrast,
it was shown that SMRT (20) and N-CoR (8),
nuclear receptor corepressors, form complexes with Sin3 and histone
deacetylase proteins (19, 40).
CBP and p300 define a distinct class of coactivator molecules,
functionally interacting with many different transcription factors, including nuclear receptors, CREB, NF-
B, bHLH
factors, p53, STATs, AP-1, and SRF-TCF (reviewed in reference
16). In particular, CBP and p300 have been found to
interact directly with nuclear receptors in a ligand- and AF2-dependent
manner (7, 18, 23, 54). Interestingly, CBP-p300 was recently
found to interact with SRC-1 (54) and form a complex with a
series of cellular proteins with molecular masses ranging from 44 to 270 kDa (11). SRC-1 and p/CIP were recently shown to
coactivate multiple transcription factors, including CREB and STATs
(48), NF-
B (39), AP-1 (32), and SRF
(26). Based on this broad spectrum of action, these proteins
(i.e., CBP-p300 and SRC-1) were renamed transcription integrators.
Herein, we describe the initial characterizations of a novel protein,
ASC-1, originally isolated based on its association with nuclear
receptors (31). ASC-1 is a transcription coactivator of
nuclear receptors, associating with specific components of the RNA
polymerase II complex, the hinge domain of nuclear receptors, and
transcription integrators SRC-1 and CBP-p300. Strikingly, ASC-1, a
nuclear protein, localizes to the cytoplasm under conditions of serum
starvation but is retained in the nucleus when serum starved in the
presence of ligand or coexpressed CBP or SRC-1, raising an interesting
possibility that ASC-1 may play an important role in establishing
distinct coactivator complexes under different cellular conditions.
 |
MATERIALS AND METHODS |
Antibodies and plasmids.
A monoclonal antibody against
hemagglutinin (HA) epitope and fluorescein isothiocyanate
(FITC)-rhodamine-conjugated antibodies as well as rabbit
polyclonal antibodies against retinoic acid receptor alpha
(RAR
) were purchased from Boehringer (Mannheim, Germany). A
rabbit polyclonal antibody was raised and affinity purified against
the ASC-1 zinc finger region (the ASC-1 residues 125 to 237). A
PCR-amplified fragment encoding a full-length ASC-1 was cloned into
EcoRI and XhoI restriction sites of pJ3H (kind gift of J. K. Chung at KAIST, Korea) to express HA-tagged ASC-1 in
mammalian cells. ASCdn, a mutant ASC-1 deleted for the zinc finger
region (the ASC-1 residues 165 to 216), was constructed by using
two-step PCR procedures (2). LexA, B42, T7, glutathione S-transferase (GST), and Gal4 fusion vectors to express
ASC-1, ASC
N, ASC
N
C, p300-N, p300-C, and CBP-C were constructed
by inserting appropriate PCR fragments into EcoRI and
XhoI/SalI sites of p202PL (2),
pJG4-5 (2), pcDNA3 (Invitrogen, San Diego, Calif.),
pGEX4T-1 (Amersham Pharmacia Biotech), and pCMX-GAL4-N (kind gift of
Ron Evans at the Salk Institute), respectively. PCR fragments encoding
the TR
1 residues 164 to 265 and 260 to 444 were inserted into
EcoRI and SalI sites of p202PL to express LexA-TR-D and LexA-TR-E, respectively. LexA vectors to express B42,
retinoid X receptor (RXR)-DEF, thyroid hormone receptor (TR)-DEF, TR-DEF459, SRC-C and SRC-D as well as T7 vectors to express SMRT, SRC-1, SRC-C, and SRC-D were as previously described (2, 20, 29,
32, 33, 39). GST-vectors encoding RXR, RXR
AF2, RAR, TR,
estrogen receptor alpha (ER
), SRC-1, CBP-1, CBP-5, TBP, and TFIIA,
the mammalian expression vectors for Gal4-VP16, p300, SRC-1, TR, RAR,
ER
, and RXR, the transfection indicator construct pRSV-
-gal as
well as the reporter constructs TREpal-LUC, ERE-LUC, DR5-LUC, and
Gal4-TK-LUC were as previously described (29, 32, 39, 57).
Northern and Western blot analyses.
An RNA blot (Clontech,
Palo Alto, Calif.) containing 2 µg of poly(A)+
(polyadenylated) RNA from various human tissues was hybridized with a
random-primed 32P-labeled DNA probe (encompassing amino
acids 125 to 237 of ASC-1) and exposed on X-ray film, as described
(2). Western analyses were done as previously described
(2).
GST pull-down assays.
Approximately 2 to 4 µg of the GST
fusions or GST alone expressed in Escherichia coli was bound
to glutathione-Sepharose-4B beads (Pharmacia, Piscataway, N.J.), and
incubated with labeled proteins expressed by in vitro translation by
using the TNT-coupled transcription-translation system, with conditions
as recommended by the manufacturer (Promega, Madison, Wis.).
Specifically bound proteins were eluted from beads with 40 mM reduced
glutathione in 50 mM Tris (pH 8.0) and analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
autoradiography as described (2). Where total nuclear
extracts were used, Western analysis was exploited to confirm specific
bindings as indicated (see Fig. 4B).
Yeast two-hybrid test.
For the yeast two-hybrid tests,
plasmids encoding LexA fusions and B42 fusions were cotransformed into
Saccharomyces cerevisiae EGY48 containing the
lacZ reporter plasmid, SH/18-34 (2). Plate and
liquid assays of
-gal expression were carried out as described (29). Similar results were obtained in more than two similar experiments.
Immunofluorescence.
Rat-1 fibroblast cells were
microinjected with HA-tagged ASC-1 plasmid (25 µg/ml) and fixed at
indicated times after serum starvation, followed by indirect
immunostaining with anti-HA antibody and FITC-rhodamine-conjugated
antibodies as previously described (21). The image was
photographed with a Zeiss AxioplanII camera equipped with PIXERA.
Cell culture and transfections.
HeLa or CV-1 cells were
grown in 24-well plates with medium supplemented with 10% fetal calf
serum for 24 h and were transfected with 100 ng of lacZ
expression vector pRSV-
-gal and 100 ng of a luciferase reporter
gene, along with various expression vectors. Total amounts of
expression vectors were kept constant by adding appropriate amounts of
pcDNA3. These cells were incubated, either in the presence or absence
of 0.1 µM of ligand, with medium containing 10% fetal calf serum for
36 h. Cells were then harvested, luciferase activity was assayed
as described (2), and the results were normalized to the
lacZ expression. Similar results were obtained in more than
two similar experiments.
 |
RESULTS |
Isolation of a full-length segment of cDNA encoding ASC-1.
TRIP4 was isolated as a partial clone of a protein that specifically
interacts with a series of nuclear receptors including TR and RXR
(31). On the basis of its ability to functionally interact
with nuclear receptors and other signal-dependent transcription factors
(unpublished data), we have renamed this protein ASC-1. ASC-1 is
encoded by an approximately 2,300-nucleotide mRNA which is expressed in
all the human and mammalian tissues examined (Fig. 1 and results not shown). Extensive
screening of a few human cDNA libraries produced a number of
full-length cDNA clones in which the initiator methionine is preceded
by a few in-frame stop codons. Overall, ASC-1 shows no significant
homology to any gene or protein in current databases. However, ASC-1
contains a putative zinc finger motif with an arrangement of metal
binding residues similar to those of E1A (14) and a putative
regulatory factor VAC1 (51) (i.e.,
CX2CX12-13CX2CX4C)
(Fig. 2A).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
Expressions of ASC-1. An RNA blot (Clontech) containing
2 µg of poly(A)+ mRNA from the indicated human tissues
was hybridized with an ASC-1 probe under standard conditions
(2). Equivalent loading was verified by hybridization with
an actin cDNA probe (results not shown). S.I., small intestine; P.B.L.,
peripheral blood leukocyte. Size markers are as indicated.
|
|

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 2.
(A) ASC-1 amino acid sequence. Two potential nuclear
localization signals are underlined. Cysteine and histidine residues
are indicated in boldface (those conserved with E1A
[14] and VAC1 [51] are underlined).
The positions of the deletions in ASC N and ASC N C are indicated
by arrows. (B) Schematic diagram of ASC-1 and its deletion mutants. The
putative zinc finger domain is as indicated. ASC N consists of the
ASC-1 residues 125 to 581, and ASC N C includes only the putative
zinc finger domain (residues 125 to 237). The zinc finger region
is specifically deleted in ASCdn (i.e., the ASC-1 residues 165 to
216).
|
|
ASC-1 contains a distinct autonomous transactivation domain.
Previous results in yeast demonstrated that the originally isolated
TRIP4 clone, referred to here as ASC
N (Fig. 2B), was able to
activate transcription when fused to LexA (31). Since a
similar transactivation was also observed with LexA fusions to a
full-length ASC-1 and ASC
N
C, which consists only of the putative
zinc finger domain (residues 125 to 237), this transactivation function
maps to the zinc finger region (Fig. 3A).
Similarly, GAL4 fusions to a full-length ASC-1 and ASC
N
C
stimulated, in a dose-dependent manner, expression of the GAL4-LUC
reporter construct (13) in mammalian cells (Fig. 3B and
results not shown). This autonomous transactivation function associated
with ASC-1, particularly in yeast, where nuclear receptors do not
exist, led us to examine if ASC-1 directly associates with basal
transcription factors TBP and TFIIA (reviewed in reference
4). Indeed, ASC-1 readily interacted with both
proteins in vitro, whereas SRC-1 interacted only with TBP (Fig. 3C). In
contrast, I
B
did not interact with either protein. Similar
results were obtained with ASC
N
C (results not shown), indicating
that the zinc finger region is sufficient for these interactions.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Autonomous transactivation function of ASC-1. (A) The
yeast one-hybrid results. The indicated LexA-plasmids were transformed
into a yeast strain containing an appropriate lacZ reporter
gene, as described (29). The results are expressed as
induction fold (n-fold) over the value obtained with
LexA/ , which was given an arbitrary value of 1. The data are
representative of at least two similar experiments and the standard
deviations were less than 5%. (B) CV-1 cells were transfected with
lacZ expression vector and increasing amounts of
Gal4-ASC-1-expression vector, along with a reporter construct
Gal4-TK-LUC, as described. Similar results were also obtained with HeLa
cells and Gal4-ASC N C (results not shown). The results are
expressed as n-fold over the value obtained with 100 ng of
Gal4/N, which was given an arbitrary value of 1. The data are
representative of at least two similar experiments, and the standard
deviations were less than 5%. (C) In vitro interaction of ASC-1 with
basal factors. Bacterially produced GST-TBP, GST-TFIIA, or GST alone
was bound to a glutathione-agarose column and incubated with equivalent
amounts of the indicated 35S-labeled ASC-1, SRC-1, or
I B produced by in vitro translation, as described (2).
Specifically bound proteins were released by glutathione and resolved
by SDS-PAGE. Approximately 20% of the labeled proteins used in the
binding reactions were loaded as inputs.
|
|
ASC-1 binds the hinge domain of nuclear receptors.
Western
analysis revealed that endogenous ASC-1 in HeLa cells is, as expected,
a predominantly nuclear protein of approximately 68 kDa (Fig.
4A). In addition, HeLa nuclear extracts
specifically retained GST fusions to TR, and ER
contained ASC-1,
either in the presence or absence of ligand (Fig. 4B). As previously
reported (31), coexpression of the B42-ASC
N or
B42-ASC
N
C fusion protein and a LexA fusion to either the TR-DEF
or the RXR-DEF domains stimulated LacZ expression in yeast,
which became further enhanced in the presence of their ligands, T3 and
9-cis-RA (results not shown). Similar results were also
obtained with a B42 fusion to the full-length ASC-1 (Fig.
5A). These results suggested either ligand-dependent interaction between ASC-1 and receptors or
ASC-1-mediated transcriptional coactivation of ligand-dependent
transactivation in yeast. Since the C-terminal AF2 core helix of the
receptors is the target for other ligand-dependent coactivators, we
examined whether the zinc finger region of ASC-1 contacts this AF2 core region. However, all of the ASC-1 constructs interacted in a
T3-independent manner with LexA-TR-DEF459, a previously
described mutant TR in the AF2 core region (29). In
addition, ASC-1 didn't show any interaction with the N-terminal ABC
domains of RXR (RXR-ABC) and all of the ASC-1 fusions to B42
specifically bound a LexA fusion including only the hinge region of TR
(LexA-TR-D), but did not bind a LexA fusion to the TR-LBD
(LexA-TR-E). Overall, these results suggest that ligand-independent
contacts between the ASC-1 zinc finger domain and the receptor hinge
domain are a major component of their interaction.

View larger version (7K):
[in this window]
[in a new window]
|
FIG. 4.
Expression of endogenous ASC-1 in HeLa cells. (A) HeLa
cells were fractionated into nuclear (NE) and cytosolic (S-100)
fractions as described (2) and were probed with indicated
antibodies by Western analysis. -RPB1 and -SRC-1 are
monoclonal antibodies against the RNA polymerase II largest subunit
(8WG16) and SRC-1, respectively. (B) HeLa nuclear extracts were
incubated with bacterially expressed GST-fusions to TR and ER or GST
alone either in the presence or absence of ligand, as indicated.
Specifically bound proteins were released by glutathione, resolved by
SDS-PAGE, and probed with a rabbit polyclonal antibody against ASC-1 by
Western analysis. Approximately 20% of the nuclear extracts used in
the binding reactions were loaded as an input.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
ASC-1 interacts with nuclear receptors. (A) The
indicated B42 and LexA plasmids were transformed into a yeast strain
containing an appropriate lacZ reporter gene, as described
(29). TR-D and TR-E include the rat TR 1 residues 164 to
265 (the hinge domain) and 260 to 444 (the LBD), respectively. Open and
stippled boxes indicate the presence of B42 alone, whereas hatched and
closed boxes indicate the presence of B42-ASC-1. Stippled and closed
boxes include 1 µM T3 or 9-cis-RA. The results are
expressed as induction fold (n-fold) over the value obtained
with LexA/ and B42 alone, which was given an arbitrary value of 1. The data are representative of at least two similar experiments and the
standard deviations were less than 5%. Similar results were also
obtained with ASC N and ASC N C. (B) In vitro interaction of
ASC-1 with nuclear receptors. Bacterially produced GST alone or GST
fusions to RAR , TR , ER , RXR, and RXR AF2 (57)
were bound to a glutathione-agarose column and incubated with
equivalent amounts of the indicated 35S-labeled ASC-1 or
SRC-1 produced by in vitro translation, as described (2). +,
presence of 0.1 µM of each cognate ligand. Approximately 20% of the
labeled proteins used in the binding reactions were loaded as inputs.
(C) Ligand-dependent interaction of ASC-1 with TR in the presence of
SMRT (20). GST alone or GST-TR bound to a
glutathione-agarose column was incubated with ASC-1 or SMRT labeled by
in vitro translation. +, presence of 0.1 µM T3. Approximately 20% of
the labeled proteins used in the binding reactions were loaded as
inputs.
|
|
These results were further confirmed by direct in vitro binding. As
shown in Fig. 5B, ASC-1 interacted in a ligand-independent manner with
GST fusions to RXR, RAR, TR, and ER
, but did not bind luciferase and
other control proteins (results not shown). Similar to the yeast
results with LexA-TR-DEF459, ASC-1 interacted with RXR
AF2, a
recently described AF2 mutant (57), in a
9-cis-RA-independent fashion. Similar results were also
obtained with ASC
N
C (results not shown). However, SRC-1 bound
only the wild-type RXR as well as RAR, TR, and ER
in a
ligand-dependent manner, as expected (42). N-CoR
(8) and SMRT (20) bind to the hinge regions of
unliganded receptors that appear to overlap the binding site for ASC-1.
Indeed, ASC-1 interacted with TR in a ligand-dependent manner when SMRT
was added in the in vitro binding reactions (Fig. 5C), probably due to
competitive bindings between ASC-1 and SMRT, since SMRT interacted only
with unliganded TR as previously described (20). These
results strongly suggest that the receptor-ASC-1 interactions are
ligand-dependent in vivo, as these corepressor molecules are
ubiquitously expressed in most tissues (8, 20).
ASC-1 binds to integrators SRC-1 and CBP-p300.
Surprisingly,
ASC-1 was also found to associate with transcription integrator SRC-1
(26, 32, 39, 48) in yeast (Fig. 6A). In particular, the interaction was
mapped to a subregion of SRC-1 (i.e., SRC-D, residues 759 to 1141),
encompassing the previously defined CBP-p300 binding domain (18,
23, 42, 54). Consistent with these yeast results, ASC-1 also
interacted with SRC-D (residues 759 to 1141) but not with SRC-C
(residues 568 to 779) in vitro, whereas liganded RXR interacted only
with SRC-C (Fig. 6B), as previously described (42). In
addition, ASC-1 associated with transcription integrator CBP-p300
(16) in yeast (Fig. 6C). ASC-1 interacted with p300-C (the
p300 residues 2041 to 2157) and CBP-C (the CBP residues 1868 to 2441)
but not with p300-N (the p300 residues 1 to 117), localizing the
interaction domain to a subregion of CBP-p300 that includes the
previously defined SRC-1 binding sites (i.e., the p300 residues 2041 to
2157) (18, 23, 42, 54). These yeast results were also
confirmed by direct in vitro bindings, in which ASC-1 interacted with
CBP-5 (residues 1891 to 2441) but not with CBP-1 (residues 1 to 450), whereas p65 interacted with both (Fig. 6D), as previously reported (15). Similar results were also obtained with ASC
N and
ASC
N
C (results not shown), indicating that the zinc finger region
is sufficient for all of these interactions.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
ASC-1 interacts with SRC-1-CBP-p300. (A) The indicated
B42 and LexA plasmids were transformed into a yeast strain containing
an appropriate lacZ reporter gene, as described
(29). SRC-C and SRC-D include the SRC-1 residues 568 to 779 and 759 to 1141, respectively. Open boxes indicate B42 alone, whereas
stippled, hatched, and closed boxes indicate the presence of B42
fusions to ASC-1, ASC N, and ASC N C, respectively. The results
are expressed as induction fold (n-fold) over the value
obtained with LexA/ and B42 alone, which was given an arbitrary value
of 1. The data are representative of at least two similar experiments
and the standard deviations were less than 5%. (B) GST alone,
GST-ASC-1, or GST-RXR bound to a glutathione-agarose column was
incubated with SRC-C or SRC-D labeled by in vitro translation. +,
presence of 0.1 µM 9-cis-RA. Approximately 20% of the
labeled proteins used in the binding reactions were loaded as inputs.
(C) The indicated B42 and LexA plasmids were transformed into a yeast
strain containing an appropriate lacZ reporter gene, as
described (29). CBP-C includes the CBP residues 1868 to
2441, whereas p300-N and p300-C include the p300 residues 1 to 117 and
2041 to 2157, respectively. Open boxes indicate B42 alone, whereas
stippled, hatched, and closed boxes indicate the presence of B42
fusions to p300-N, p300-C, and CBP-C, respectively. The results are
expressed as n-fold over the value obtained with LexA/ and
B42 alone, which was given an arbitrary value of 1. The data are
representative of at least two similar experiments and the standard
deviations were less than 5%. (D) GST alone, GST-CBP-1, or GST-CBP-5
bound to a glutathione-agarose column was incubated with ASC-1 or p65
labeled by in vitro translation. Approximately 20% of the labeled
proteins used in the binding reactions were loaded as inputs.
|
|
The zinc finger region of ASC-1 forms a ternary complex with CBP,
SRC-1, and RXR.
It was surprising that a relatively small region
of the ASC-1 (residues 125 to 237) encompassing the putative zinc
finger motif was found to be responsible for interactions with
receptors, SRC-1, CBP-p300, and basal factors. In addition, ASC-1
interacted with a region in SRC-1 that encompasses the
CBP-p300-interaction domain (54). Similarly, ASC-1
interacted with a region in CBP-p300 that was previously shown to
contain the SRC-1 binding site (54). Thus, we examined
whether the zinc finger region of ASC-1 is able to form a ternary
complex with these proteins. CBP-C (the CBP residues 1868 to 2441)
contains the SRC-1 binding domain, whereas SRC-D (the SRC-1 residues
759 to 1141) includes the CBP-p300 binding domain. However, CBP-C and
SRC-D do not include the domains interacting with nuclear receptors. As
shown in Fig. 7, radiolabeled CBP-C, a
full-length RXR, and SRC-D efficiently bound to a GST fusion to
ASC
N
C but not GST alone in vitro. Inclusion of increasing amounts
of unlabeled RXR disrupted bindings of radiolabeled RXR and
ASC
N
C, as expected, but not the ASC
N
C-CBP-C and
ASC
N
C-SRC-D interactions (Fig. 7A). These results demonstrate
that the zinc finger region of ASC-1 (i.e., ASC
N
C) and RXR can
form a ternary complex with either CBP-C or SRC-D. Similarly,
ASC
N
C and SRC-D were found to form a ternary complex with CBP-C
or RXR (Fig. 7B). In particular, it was notable that the
CBP-C-ASC
N
C interactions became further stimulated in the
presence of SRC-D. From these results, we concluded that the zinc
finger region of ASC-1 is capable of forming a ternary complex with
CBP, SRC-1, and RXR.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 7.
ASC-1 forms a ternary complex with RXR, CBP, and SRC-1.
GST alone or GST-ASC N C bound to a glutathione-agarose column was
incubated with CBP-C, RXR, or SRC-D labeled by in vitro translation.
Increasing amounts of RXR (A) or SRC-D (B), in vitro translated in the
absence of [35S]methionine, was added to the binding
reaction as a competitor, as indicated. Approximately 20% of the
labeled proteins used in the binding reactions were loaded as inputs.
|
|
ASC-1 relocates between nucleus and cytosol, depending on different
cellular conditions.
The HA-tagged, overexpressed ASC-1 was
normally found exclusively in the nucleus, as expected (results not
shown). In contrast, it accumulated in the cytoplasm in a
time-dependent manner when deprived of serum (Fig.
8A). ASC-1 was found throughout the
cytoplasm and nucleus after 6 h of serum starvation, whereas it
was found mostly in the cytoplasm after 24 to 48 h of starvation.
Interestingly, when 9-cis-RA or serum was added after
24 h of serum starvation, ASC-1 was found exclusively in nucleus
24 h later (Fig. 8A). Similarly, the cytoplasmic accumulation was
not observed when cells were serum starved for 24 h in the
presence of ligand or coexpressed CBP or SRC-1, resulting in nuclear
localization of ASC-1 (Fig. 8B). Similar results were also
obtained with charcoal-stripped serum (results not shown). Taken
together, these results indicate that localization of ASC-1 is tightly
regulated under different cellular conditions, and ASC-1 can directly
associate with CBP, SRC-1, and liganded receptors in vivo.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 8.
Association of ASC-1 with SRC-1, CBP, and liganded
receptor in vivo. (A) Time-dependent accumulation of ASC-1 to cytoplasm
in serum-starved cells. Rat-1 fibroblast cells were microinjected with
HA-tagged ASC-1 plasmid (25 µg/ml) and fixed at indicated times
during serum starvation, followed by indirect immunostaining with
anti-HA antibody and FITC-rhodamine-conjugated antibodies as previously
described (21). Serum (10%) or 0.1 µM 9-cis-RA
was added to the media following 24 h of serum starvation and was
observed 24 h later by indirect immunostaining, as indicated. The
image was photographed with a Zeiss AxioplanII camera equipped with
PIXERA. The picture is representative of approximately 50 injected
cells which gave similar results. Similar results were also obtained
with HeLa cells (results not shown). (B) Inhibition of cytoplasmic
accumulation of ASC-1 by ligand, SRC-1, or CBP in serum-starved cells.
Rat-1 fibroblast cells were microinjected with either HA-tagged ASC-1
(25 µg/ml) alone, HA-tagged ASC-1 plus SRC-1 (25 µg/ml each), or
HA-tagged ASC-1 plus CBP (25 µg/ml each), were serum starved for
24 h either in the presence or absence of 0.1 µM
9-cis-RA as indicated, and were processed for
immunostaining. Similar results were also obtained with HeLa cells
(results not shown).
|
|
ASC-1 as a novel transcription coactivator of nuclear
receptors.
To assess the functional consequences of these
interactions, ASC-1 was cotransfected into CV-1 cells along with a
reporter construct, TREpal-LUC. Increasing amounts of
cotransfected ASC-1 enhanced the
9-cis-RA-dependent activation of this reporter in a
dose-dependent manner, with cotransfection of 100 ng of ASC-1 increasing the activation approximately fivefold. Consistent with the
specific interactions of ASC-1 with SRC-1 and CBP, the ASC-1-enhanced level of the reporter gene expression was further stimulated by cotransfected SRC-1 or by the CBP homologue p300 (Fig.
9A). A mutant ASC-1 deleted for the zinc
finger domain (ASCdn) showed a strong dominant-negative phenotype;
coexpression of ASCdn impaired the 9-cis-RA-dependent
activation of the reporter, either in the presence or absence of
additional wild-type ASC-1. Similar dominant-negative phenotypes were
also observed with ASC
N
C (results not shown). These results
strongly attest to the importance of ASC-1 in the nuclear receptor
transactivation function in vivo. Interestingly, ASC-1 was not able to
coactivate the RXR
AF-driven transactivations (Fig. 9B), indicating
that ASC-1 has to function in conjunction with AF2-dependent
coactivators, such as CBP and SRC-1. Similar results were also obtained
with a series of different reporter constructs responsive to ER
, TR,
RAR, or RXR in various cell types (Fig. 9C, D, and E and results not
shown). In contrast, the basal expression of the reporter in the
absence of ligand remained relatively constant with increasing amount
of cotransfected ASC-1. Similarly, ASC-1 did not affect expression of
the control plasmids pRSV-
-gal or TK-LUC (results not shown), or
GAL4-VP16-mediated transactivation of the GAL4-LUC reporter construct
(13) (Fig. 9F). These results demonstrated that ASC-1 is a
bona fide transcription coactivator molecule of nuclear receptors.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 9.
ASC-1 potentiates gene expressions mediated by nuclear
receptors. HeLa cells were transfected with -gal expression vector
and increasing amounts of ASC-1-expression vector, either in the
absence or presence of SRC-1 or p300 expression vector, along with
indicated reporter constructs, as described. For specific activation of
each reporter construct, 10 ng of RXR (A), 50 ng of RXR AF2 (B), 10 ng of ER (C), 10 ng of TR (D), 10 ng of RAR (E), or 50 ng of
Gal4-VP16 (F) was also added. Hatched boxes indicate the presence of
0.1 µM each cognate ligand. The results are expressed as induction
fold (n-fold) over the value obtained in the absence of
ligand and ASC-1, which was given an arbitrary value of 1. The data are
representative of at least two similar experiments, and the standard
deviations were less than 5%. Similar results were also obtained with
CV-1 cells (results not shown).
|
|
 |
DISCUSSION |
Transcription coactivators (reviewed in reference
45) can function not only to transmit the signal of
ligand-induced conformational change to the basal transcription
machinery but also to modulate chromatin structure. In this report, we
have described the initial characterization of ASC-1, which shows
various properties consistent with its role as a novel transcription
coactivator molecule of nuclear receptors. These include associations
with nuclear receptors (Fig. 4 and 5), the basal transcription
machinery (Fig. 3), and transcription integrators CBP and SRC-1 (Fig.
6), an autonomous transactivation function (Fig. 3), and coactivation
of transactivation mediated by nuclear receptors (Fig. 9).
The interactions of ASC-1 with nuclear receptors are ligand independent
in vitro (Fig. 5B), whereas inclusion of SMRT (20) in the
binding reactions resulted in ligand-dependent interactions of ASC-1
with receptors (Fig. 5C). The hinge domain of nuclear receptor is a
major determinant in interactions with ASC-1 (Fig. 5A) as well as SMRT
(20). Since SMRT is released from liganded nuclear receptors
and ASC-1 is still able to bind to liganded receptors, the
receptor-ASC-1 bindings should become ligand dependent in vivo, where
SMRT is ubiquitously expressed. The indirect immunofluorescence results
are also consistent with this notion (Fig. 8). However, it was
intriguing that the relatively strong basal interactions of ASC-1 with
receptors were further stimulated by ligand in yeast, whereas the
interactions of ASC-1 with TR-DEF459, a previously described AF2 mutant
TR (29), were not. These results may have been caused simply
by ligand-induced stabilization of receptor conformation to facilitate
the ASC-1-receptor interactions in yeast. Alternatively, proteins
functionally homologous to SMRT, an AF2-dependent coactivator such as
SRC-1-CBP-p300, or both may exist in yeast, and ASC-1 may cooperate
with these putative yeast proteins to mediate the ligand- and
AF2-dependent coactivation of nuclear receptors in yeast. In this
regard, it is notable that our database search revealed the highly
conserved ASC-1 homologues in the higher eukaryotes
Caenorhabditis elegans and Schizosaccharomyces pombe as well as a relatively distant ASC-1 homologue in S. cerevisiae (results not shown).
Recent biochemical studies suggest that transcription coactivators
function as a complex with other related proteins (45). Thus
far, several groups of such distinct macromolecular complexes have been
described. The TAF components of TFIID (reviewed in reference
4) and the SRB-MED components bound to polymerase II
(reviewed in reference 38) comprise those that are
ultimately associated with the general transcription machinery.
B-cell-specific OCA-B (35), a group of distinct nuclear
proteins named thyroid hormone receptor associated proteins (TRAPs)
(12), and a transcriptionally active nuclear complex that
interacts only with liganded vitamin D receptor (VDR) (DRIPs)
(43) define a group of coactivator complexes with rather
specific functions. TRAPs purified from HeLa cells grown in the
presence of thyroid hormone (T3) were found to markedly activate
transcription by liganded TR in vitro, whereas DRIPs consisting of a
complex of at least 10 different proteins ranging from 65 to 250 kDa
were found to coactivate the VDR-dependent transactivation. The DRIPs
were distinct from the CBP-p300 complex, although like these
coactivators, their interaction also required the AF2 transactivation
motif of VDR (43). Finally, the CBP-p300 coactivator complex
defines a distinct coactivator complex that directly binds and
coactivates a wide spectrum of different transcription factors. In
particular, CBP-p300 was found to be complexed with SRC-1 (18, 23,
42, 54) and a series of cellular proteins with molecular masses
ranging from 44 to 270 kDa (11). Purification and analysis
of various proteins in this group revealed that they are components of
the human SWI-SNF complex and that p270 is an integral member of this
complex. In addition, different classes of mammalian transcription
factors
nuclear receptors, CREB, and STATs
were recently shown to
functionally require distinct components of the CBP-p300 coactivator
complex, based on their platform or assembly properties
(27). RAR, CREB, and STATs were further demonstrated to
require different histone acetyltransferase activities within the
CBP-p300 complex to activate transcription. Recently, p300 and CBP,
despite their similarities, have been shown to have distinct functions
during retinoid-induced differentiation of embryonic carcinoma F9 cells
(24). Overall, these results suggest that distinct
coactivator complexes appear to exist among CBP-p300-containing
coactivator complexes in the cell, which should be responsive to
distinct activating signals and differentially integrate various
signaling pathways.
We have presented a few pieces of experimental evidence that support
direct associations of ASC-1 with SRC-1 and CBP-p300. First, ASC-1 was
shown to physically bind CBP-p300 and SRC-1, as demonstrated by the
yeast two-hybrid tests and the GST pull-down assays (Fig. 6). Second,
ASC-1 was found to colocalize, at least under serum-starved conditions,
with CBP and SRC-1 in vivo, as demonstrated by the indirect
immunofluorescence of Rat-1 fibroblast cells (Fig. 8). Finally, while
the ASC-1 interaction domain does not include the AF-2 domain of
nuclear receptors (Fig. 5), ASC-1 was shown to cooperate with SRC-1 and
p300 in coactivating transactivation by nuclear receptors (Fig. 9A). In
addition, ASC-1 was not able to coactivate the mutant RXR that lacks
the AF2 domain (i.e., RXR
AF2) (Fig. 9B), clearly indicating that
ASC-1 has to function in conjunction with AF2-dependent factors such as
CBP-p300 and SRC-1. These results suggest that ASC-1 may represent an
active member of the CBP-p300 complexes, along with SRC-1 and related proteins. Alternatively, it may represent a constituent of distinct coactivator complexes that, in turn, functionally interact with the
CBP-SRC-1 complexes. Consistent with the latter possibility, it was
recently shown that CBP, p300, and SRC-1 exist as distinct steady-state
coactivator complexes in vivo (37). In addition, we have
also isolated a novel complex of proteins from HeLa nuclei based on
their tight association with ASC-1 which exhibited a fractionation
profile distinct from that of CBP, p300, or SRC-1 and didn't appear to
contain any of these proteins (unpublished results).
One of the most striking features of ASC-1 was its interesting
relocation property (Fig. 8). When deprived of serum, ASC-1 accumulated
in cytoplasm, while it was exclusively nuclear in the presence of
ligand or coexpressed CBP or SRC-1. However, it is not known whether
this cytoplasmic accumulation under conditions of serum deprivation is
due to the inability of newly synthesized ASC-1 to enter the nucleus or
active relocation of the existing nuclear ASC-1 to the cytoplasm.
Nonetheless, these relocation properties raise an interesting
possibility that ASC-1 may play a critical role in establishing
distinct coactivator complexes under different cellular conditions (as
summarized in Fig. 10). When deprived
of serum, for instance, coactivator complexes devoid of ASC-1 may
predominate within the nucleus (due to the cytoplasmic accumulation of
ASC-1), which may preferentially transactivate a set of transcription
factors activated by serum starvation while shutting down general
transcription activities. Candidate genes potentially regulated by
these non-ASC-1-containing coactivator complexes include those
specifically expressed at growth arrest (10, 22, 44). It is
also notable that ASC-1 is likely to function with transcription
factors other than nuclear receptors, based on its associations with
SRC-1 and CBP, which in turn functionally interact with transcription
factors in diverse signaling pathways. Indeed, we have found that ASC-1
is required for transactivation by multiple transcription factors,
including AP-1 and NF-
B (unpublished data).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 10.
Model of ASC-1 actions. Distinct putative coactivator
complexes, each containing ASC-1, SRC-1, or CBP, exist in vivo
(37 and unpublished results) and mediate
transactivations by a number of distinct transcription factors. Each of
these complexes recognizes a discrete part or subunit of target
transcription factors and may cooperate with each other for efficient
coactivation. Alternatively, these distinct coactivator complexes may
form a larger supracomplex, as suggested by direct bindings among
SRC-1, CBP, and ASC-1. Serum starvation may lead to enrichment of
non-ASC-1-containing coactivator complexes within the nucleus, which
may preferentially regulate genes turned on under serum-deprived
conditions.
|
|
In conclusion, we have described a novel coactivator molecule capable
of associating with liganded receptors, SRC-1, and CBP in vivo and
which may play a critical role in integrating different cellular
conditions into the transcription machinery. Surprisingly, all of the
functions of ASC-1 described in this report appear to require only the
putative zinc-binding domain, whereas the actions of the much larger
CBP, p300, and SRC-1 proteins are dependent on distinct
interaction domains for their various targets. However, it should be
noted that only some of these interactions are likely to exist
within the ASC-1-containing complex. Finally, it's notable that ASC-1 contains multiple phosphorylation sites,
potentially responsive to various signals, suggesting that ASC-1 may
directly respond to various cellular regulatory signals. Overall,
studies of this coactivator protein should provide important
insights into the multifactorial control of biological processes under regulation of multiple signal transduction pathways in vivo.
 |
ACKNOWLEDGMENTS |
We thank Ming Tsai, J. K. Chung, David Livingston, and
Ronald Evans for plasmids and antibodies. We also thank Soo-Kyung Lee for the plasmids encoding LexA-TR-D and LexA-TR-E.
This work was supported in part by grants from the NIH to D.D.M. and
the Korean Ministry of Health and Welfare to B.H.J. Y.C.L. and
J.W.L. are supported by the National Creative Research Initiatives of
the Korean Ministry of Science and Technology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Center for
Ligand and Transcription, Chonnam National University, Kwangju
500-757, Korea. Phone: 82-62-530-0910. Fax: 82-62-530-0772. E-mail: jlee{at}chonnam.chonnam.ac.kr.
 |
REFERENCES |
| 1.
|
Anzick, S. L.,
J. Kononen,
R. L. Walker,
D. O. Azorsa,
M. M. Tanner,
X. Y. Guan,
G. Sauter,
O. P. Kallioniemi,
J. M. Trent, and P. S. Meltzer.
1997.
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.
Science
277:965-968[Abstract/Free Full Text].
|
| 2.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl (ed.).
1995.
Current protocols in molecular biology.
Greene Associates, New York, N.Y.
|
| 3.
|
Bannister, A. J., and T. Kouzarides.
1996.
The CBP co-activator is a histone acetyltransferase.
Nature
384:641-643[Medline].
|
| 4.
|
Burley, S. K., and R. G. Roeder.
1996.
Biochemistry and structural biology of transcription factor IID (TFIID).
Annu. Rev. Biochem.
65:769-799[Medline].
|
| 5.
|
Cavailles, V.,
S. Dauvois,
F. L'Horset,
G. Lopez,
S. Hoare,
P. J. Kushner, and M. G. Parker.
1995.
Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.
EMBO J.
14:3741-3751[Medline].
|
| 6.
|
Cavailles, V.,
S. Dauvois,
P. S. Danielian, and M. G. Parker.
1994.
Interaction of proteins with transcriptionally active estrogen receptors.
Proc. Natl. Acad. Sci. USA
91:10009-10013[Abstract/Free Full Text].
|
| 7.
|
Chakravarti, D.,
V. J. LaMorte,
M. C. Nelson,
T. Nakajima,
I. G. Schulman,
H. Juguilon,
M. Montminy, and R. M. Evans.
1996.
Role of CBP/p300 in nuclear receptor signaling.
Nature
383:99-103[Medline].
|
| 8.
|
Chen, J. D., and R. M. Evans.
1995.
A transcriptional corepressor that interacts with nuclear hormone receptors.
Nature
377:454-457[Medline].
|
| 9.
|
Chen, H.,
R. J. Lin,
R. L. Schiltz,
D. Chakravarti,
A. Nash,
L. Nagy,
M. L. Privalsky,
Y. Nakatani, and R. M. Evans.
1997.
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.
Cell
90:569-580[Medline].
|
| 10.
|
Coccia, E. M.,
C. Cicala,
A. Charlesworth,
C. Ciccarelli,
G. B. Rossi,
L. Philipson, and V. Sorrentino.
1992.
Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation, and development.
Mol. Cell. Biol.
12:3514-3521[Abstract/Free Full Text].
|
| 11.
|
Dallas, P. B.,
I. W. Cheney,
D. W. Liao,
V. Bowrin,
W. Byam,
S. Pacchione,
R. Kobayashi,
P. Yaciuk, and E. Moran.
1998.
p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes.
Mol. Cell. Biol.
18:3596-3603[Abstract/Free Full Text].
|
| 12.
|
Fondell, J. D.,
H. Ge, and R. G. Roeder.
1996.
Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex.
Proc. Natl. Acad. Sci. USA
93:8329-8333[Abstract/Free Full Text].
|
| 13.
|
Forman, B. M.,
K. Umesono,
J. Chen, and R. M. Evans.
1995.
Unique response pathways are established by allosteric interactions among nuclear hormone receptors.
Cell
81:541-550[Medline].
|
| 14.
|
Geisberg, J. V.,
W. S. Lee,
A. J. Berk, and R. P. Ricciardi.
1994.
The zinc finger region of the adenovirus E1A transactivating domain complexes with the TATA box binding protein.
Proc. Natl. Acad. Sci. USA
91:2488-2492[Abstract/Free Full Text].
|
| 15.
|
Gerritsen, M. E.,
A. J. Williams,
A. S. Neish,
S. Moore,
Y. Shi, and T. Collins.
1997.
CREB-binding protein/p300 are transcriptional coactivators of p65.
Proc. Natl. Acad. Sci. USA
94:2927-2932[Abstract/Free Full Text].
|
| 16.
|
Goldman, P. S.,
V. K. Tran, and R. H. Goodman.
1997.
The multifunctional role of the co-activator CBP in transcriptional regulation.
Recent Prog. Horm. Res.
52:103-119.
|
| 17.
|
Halachmi, S.,
E. Marden,
G. Martin,
H. Mackay,
C. Abbondanza, and M. Brown.
1994.
Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.
Science
264:1455-1458[Abstract/Free Full Text].
|
| 18.
|
Hanstein, B.,
R. Eckner,
J. DiRenzo,
S. Halachmi,
H. Liu,
B. Searcy,
R. Kurokawa, and M. Brown.
1996.
p300 is a component of an estrogen receptor coactivator complex.
Proc. Natl. Acad. Sci. USA
93:11540-11545[Abstract/Free Full Text].
|
| 19.
|
Heinzel, T.,
R. M. Lavinsky,
T. M. Mullen,
M. Soderstrom,
C. D. Laherty,
J. Torchia,
W. M. Yang,
G. Brard,
S. D. Ngo,
J. R. Davie,
E. Seto,
R. N. Eisenman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1997.
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.
Nature
387:43-48[Medline].
|
| 20.
|
Horlein, A. J.,
A. M. Naar,
T. Heinzel,
J. Torchia,
B. Gloss,
R. Kurokawa,
A. Ryan,
Y. Kamei,
M. Soderstrom,
C. K. Glass, and M. G. Rosenfeld.
1995.
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor.
Nature
377:397-404[Medline].
|
| 21.
|
Jhun, B. H.,
D. W. Rose,
B. L. Seely,
L. Rameh,
L. Cantley,
A. R. Saltiel, and J. M. Olefsky.
1994.
Microinjection of the SH2 domain of the 85-kilodalton subunit of phosphatidylinositol 3-kinase inhibits insulin-induced DNA synthesis and c-fos expression.
Mol. Cell. Biol.
14:7466-7475[Abstract/Free Full Text].
|
| 22.
|
Ju, Y. T.,
A. C. Y. Chang,
B. R. She,
M. L. Tsaur,
H. M. Hwang,
C. C. K. Chao,
S. N. Cohen, and S. Lin-Chao.
1998.
gas7: a gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated purkinje neurons affects neurite formation.
Proc. Natl. Acad. Sci. USA
95:11423-11428[Abstract/Free Full Text].
|
| 23.
|
Kamei, Y.,
L. Xu,
T. Heinzel,
J. Torchia,
R. Kurokawa,
B. Gloss,
S. C. Lin,
R. A. Heyman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1996.
A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.
Cell
85:403-414[Medline].
|
| 24.
|
Kawasaki, H.,
R. Eckner,
T. P. Yao,
K. Taira,
R. Chiu,
D. M. Livingston, and K. K. Yokoyama.
1998.
Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation.
Nature
393:284-289[Medline].
|
| 25.
|
Kim, H.-J.,
S. K. Lee,
S.-Y. Na,
H.-S. Choi, and J. W. Lee.
1998.
Molecular cloning of xSRC-3, a novel transcription coactivator from Xenopus, that is related to AIB1, p/CIP, and TIF2.
Mol. Endocrinol.
12:1038-1047[Abstract/Free Full Text].
|
| 26.
|
Kim, H.-J.,
J. H. Kim, and J. W. Lee.
1998.
Steroid receptor coactivator-1 interacts with serum response factor and coactivates serum response element-mediated transactivations.
J. Biol. Chem.
273:28564-28567[Abstract/Free Full Text].
|
| 27.
|
Korzus, E.,
J. Torchia,
D. W. Rose,
L. Xu,
R. Kurokawa,
E. M. McInerney,
T. M. Mullen,
C. K. Glass, and M. G. Rosenfeld.
1998.
Transcription factor-specific requirements for coactivators and their acetyltransferase functions.
Science
279:703-707[Abstract/Free Full Text].
|
| 28.
|
Le Douarin, B.,
C. Zechel,
J. M. Garnier,
Y. Lutz,
L. Tora,
B. Pierrat,
D. Heery,
H. Gronemeyer,
P. Chambon, and R. Losson.
1995.
The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18.
EMBO J.
14:2020-2033[Medline].
|
| 29.
|
Lee, J. W.,
D. D. Moore, and R. A. Heyman.
1994.
A chimeric thyroid hormone receptor constitutively bound to DNA requires retinoid X receptor for hormone-dependent transcriptional activation in yeast.
Mol. Endocrinol.
8:1245-1252[Abstract].
|
| 30.
|
Lee, J. W.,
F. Ryan,
J. Swaffield,
S. Johnston, and D. D. Moore.
1995.
Interaction of thyroid hormone receptor with a conserved transcriptional mediator.
Nature
373:91-94.
|
| 31.
|
Lee, J. W.,
H. S. Choi,
J. Gyuris,
R. Brent, and D. D. Moore.
1995.
Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.
Mol. Endocrinol.
9:243-254[Abstract].
|
| 32.
|
Lee, S.-K.,
H.-J. Kim,
S.-Y. Na,
T.-S. Kim,
H.-S. Choi,
S.-Y. Im, and J. W. Lee.
1998.
Steroid receptor coactivator-1 coactivates AP-1-mediated transactivations through interactions with the c-Jun and c-Fos subunits.
J. Biol. Chem.
273:16651-16654[Abstract/Free Full Text].
|
| 33.
|
Lee, S.-K.,
H.-S. Choi,
M. R. Song,
M. O. Lee, and J. W. Lee.
1998.
Estrogen receptor, a common interaction partner for a subset of nuclear receptors.
Mol. Endocrinol.
12:1184-1192[Abstract/Free Full Text].
|
| 34.
|
Li, H.,
P. J. Gomes, and J. D. Chen.
1997.
RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.
Proc. Natl. Acad. Sci. USA
94:8479-8484[Abstract/Free Full Text].
|
| 35.
|
Luo, Y.,
H. Fujii,
T. Gerster, and R. G. Roeder.
1992.
A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors.
Cell
71:231-241[Medline].
|
| 36.
|
Mangelsdorf, D. J.,
C. Thummel,
M. Beato,
P. Herrlich,
G. Schutz,
K. Umesono,
B. Blumberg,
P. Kastner,
M. Mark,
P. Chambon, and R. M. Evans.
1995.
The nuclear receptor superfamily: the second decade.
Cell
83:835-839[Medline].
|
| 37.
|
McKenna, N. J.,
Z. Nawaz,
S. Y. Tsai,
M.-J. Tsai, and B. W. O'Malley.
1998.
Distinct steady-state nuclear receptor coregulator complexes exist in vivo.
Proc. Natl. Acad. Sci. USA
95:11697-11702[Abstract/Free Full Text].
|
| 38.
|
Myers, L. C.,
C. M. Gustafsson,
D. A. Bushnell,
M. Lui,
H. Erdjument-Bromage,
P. Tempst, and R. D. Kornberg.
1998.
The Med proteins of yeast and their function through the RNA polymerase II carboxy-terminal domain.
Genes Dev.
12:45-54[Abstract/Free Full Text].
|
| 39.
|
Na, S.-Y.,
S.-K. Lee,
S.-J. Han,
H.-S. Choi,
S.-Y. Im, and J. W. Lee.
1998.
Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates NF B-mediated transactivations.
J. Biol. Chem.
273:10831-10834[Abstract/Free Full Text].
|
| 40.
|
Nagy, L.,
H. Y. Kao,
D. Chakravarti,
R. J. Lin,
C. A. Hassig,
D. E. Ayer,
S. L. Schreiber, and R. M. Evans.
1997.
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.
Cell
89:373-380[Medline].
|
| 41.
|
Ogryzko, V. V.,
R. L. Schiltz,
V. Russanova,
B. H. Howard, and Y. Nakatani.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953-959[Medline].
|
| 42.
|
Onate, S. A.,
S. Y. Tsai,
M. J. Tsai, and B. M. O'Malley.
1995.
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.
Science
270:1354-1357[Abstract/Free Full Text].
|
| 43.
|
Rachez, C.,
Z. Suldan,
J. Ward,
C. P. Chang,
D. Burakov,
H. Erdjument-Bromage,
P. Tempst, and L. P. Freedman.
1998.
A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system.
Genes Dev.
12:1787-1800[Abstract/Free Full Text].
|
| 44.
|
Schneider, C.,
R. M. King, and L. Philipson.
1988.
Genes specifically expressed at growth arrest of mammalian cells.
Cell
54:787-793[Medline].
|
| 45.
|
Shibata, H.,
T. E. Spencer,
S. A. Onate,
G. Jenster,
S. Y. Tsai,
M. J. Tsai, and B. W. O'Malley.
1997.
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
Recent Prog. Horm. Res.
52:141-164.
|
| 46.
|
Spencer, T. E.,
G. Jenster,
M. M. Burcin,
C. D. Allis,
J. Zhou,
C. A. Mizzen,
N. J. McKenna,
S. A. Onate,
S. Y. Tsai,
M. J. Tsai, and B. W. O'Malley.
1997.
Steroid receptor coactivator-1 is a histone acetyltransferase.
Nature
389:194-198[Medline].
|
| 47.
|
Takeshita, A.,
G. R. Cardona,
N. Koibuchi,
C. S. Suen, and W. W. Chin.
1997.
TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1.
J. Biol. Chem.
272:27629-27634[Abstract/Free Full Text].
|
| 48.
|
Torchia, J.,
D. W. Rose,
J. Inostroza,
Y. Kamei,
S. Westin,
C. K. Glass, and M. G. Rosenfeld.
1997.
The transcriptional coactivator p/CIP binds CBP and mediates nuclear receptor function.
Nature
387:677-684[Medline].
|
| 49.
|
Truss, M.,
J. Bartsch,
A. Schelbert,
R. J. G. Hache, and M. Beato.
1995.
Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo.
EMBO J.
14:1737-1751[Medline].
|
| 50.
|
Voegel, J. J.,
M. J. Heine,
C. Zechel,
P. Chambon, and H. Gronemeyer.
1996.
TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.
EMBO J.
15:3667-3675[Medline].
|
| 51.
|
Weisman, L. S., and W. Wickner.
1992.
Molecular characterization of VAC1, a gene required for vacuole inheritance and vacuole protein sorting.
J. Biol. Chem.
267:618-623[Abstract/Free Full Text].
|
| 52.
|
Wong, J.,
Y.-B. Shi, and A. P. Wolffe.
1995.
A role for nucleosome assembly in both silencing and activation of the Xenopus TRbA gene by the thyroid hormone receptor.
Genes Dev.
9:2696-2711[Abstract/Free Full Text].
|
| 53.
|
Yang, X.-J.,
V. V. Ogryzko,
J. Nishikawa,
B. H. Howard, and Y. Nakatani.
1996.
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.
Nature
382:319-324[Medline].
|
| 54.
|
Yao, T. P.,
G. Ku,
N. Zhou,
R. Scully, and D. M. Livingston.
1996.
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300.
Proc. Natl. Acad. Sci. USA
93:10626-10631[Abstract/Free Full Text].
|
| 55.
|
Yeh, S., and C. Chang.
1996.
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
Proc. Natl. Acad. Sci. USA
93:5517-5521[Abstract/Free Full Text].
|
| 56.
|
Zaret, K. S., and K. R. Yamamoto.
1984.
Reversible and persistent changes in chromatin structure accompany activation of a glucocorticoid dependent enhancer element.
Cell
38:29-38[Medline].
|
| 57.
|
Zavacki, A. M.,
J. M. Lehmann,
W. Seol,
T. M. Willson,
S. A. Kliewer, and D. D. Moore.
1997.
Activation of the orphan receptor RIP14 by retinoids.
Proc. Natl. Acad. Sci. USA
94:7909-7914[Abstract/Free Full Text].
|
Molecular and Cellular Biology, September 1999, p. 6323-6332, Vol. 19, No. 9
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Li, C., Wu, R.-C., Amazit, L., Tsai, S. Y., Tsai, M.-J., O'Malley, B. W.
(2007). Specific Amino Acid Residues in the Basic Helix-Loop-Helix Domain of SRC-3 Are Essential for Its Nuclear Localization and Proteasome-Dependent Turnover. Mol. Cell. Biol.
27: 1296-1308
[Abstract]
[Full Text]
-
Grenier, J., Trousson, A., Chauchereau, A., Cartaud, J., Schumacher, M., Massaad, C.
(2006). Differential Recruitment of p160 Coactivators by Glucocorticoid Receptor between Schwann Cells and Astrocytes. Mol. Endocrinol.
20: 254-267
[Abstract]
[Full Text]
-
Iyer, L. M., Burroughs, A. M., Aravind, L.
(2006). The ASCH superfamily: novel domains with a fold related to the PUA domain and a potential role in RNA metabolism. Bioinformatics
22: 257-263
[Abstract]
[Full Text]
-
Amazit, L., Alj, Y., Tyagi, R. K., Chauchereau, A., Loosfelt, H., Pichon, C., Pantel, J., Foulon-Guinchard, E., Leclerc, P., Milgrom, E., Guiochon-Mantel, A.
(2003). Subcellular Localization and Mechanisms of Nucleocytoplasmic Trafficking of Steroid Receptor Coactivator-1. J. Biol. Chem.
278: 32195-32203
[Abstract]
[Full Text]
-
Sohn, Y.-C., Kim, S.-W., Lee, S., Kong, Y.-Y., Na, D. S., Lee, S.-K., Lee, J. W.
(2003). Dynamic Inhibition of Nuclear Receptor Activation by Corepressor Binding. Mol. Endocrinol.
17: 366-372
[Abstract]
[Full Text]
-
Mazumder, R., Iyer, L. M., Vasudevan, S., Aravind, L.
(2002). Detection of novel members, structure-function analysis and evolutionary classification of the 2H phosphoesterase superfamily. Nucleic Acids Res
30: 5229-5243
[Abstract]
[Full Text]
-
Lee, Y. S., Kim, H.-J., Lee, H. J., Lee, J. W., Chun, S.-Y., Ko, S.-K., Lee, K.
(2002). Activating Signal Cointegrator 1 Is Highly Expressed in Murine Testicular Leydig Cells and Enhances the Ligand-Dependent Transactivation of Androgen Receptor. Biol. Reprod.
67: 1580-1587
[Abstract]
[Full Text]
-
Qutob, M. S., Bhattacharjee, R. N., Pollari, E., Yee, S. P., Torchia, J.
(2002). Microtubule-Dependent Subcellular Redistribution of the Transcriptional Coactivator p/CIP. Mol. Cell. Biol.
22: 6611-6626
[Abstract]
[Full Text]
-
Jung, D.-J., Sung, H.-S., Goo, Y.-W., Lee, H. M., Park, O. K., Jung, S.-Y., Lim, J., Kim, H.-J., Lee, S.-K., Kim, T. S., Lee, J. W., Lee, Y. C.
(2002). Novel Transcription Coactivator Complex Containing Activating Signal Cointegrator 1. Mol. Cell. Biol.
22: 5203-5211
[Abstract]
[Full Text]
-
Heinlein, C. A., Chang, C.
(2002). Androgen Receptor (AR) Coregulators: An Overview. Endocr. Rev.
23: 175-200
[Abstract]
[Full Text]
-
Lee, S.-K., Na, S.-Y., Jung, S.-Y., Choi, J.-E., Jhun, B. H., Cheong, J., Meltzer, P. S., Lee, Y. C., Lee, J. W.
(2000). Activating Protein-1, Nuclear Factor-{kappa}B, and Serum Response Factor as Novel Target Molecules of the Cancer-Amplified Transcription Coactivator ASC-2. Mol. Endocrinol.
14: 915-925
[Abstract]
[Full Text]
-
Lee, S.-K., Anzick, S. L., Choi, J.-E., Bubendorf, L., Guan, X.-Y., Jung, Y.-K., Kallioniemi, O. P., Kononen, J., Trent, J. M., Azorsa, D., Jhun, B.-H., Cheong, J. H., Lee, Y. C., Meltzer, P. S., Lee, J. W.
(1999). A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo. J. Biol. Chem.
274: 34283-34293
[Abstract]
[Full Text]
-
Kretsovali, A., Spilianakis, C., Dimakopoulos, A., Makatounakis, T., Papamatheakis, J.
(2001). Self-ass